Goldman Sachs, JPMorgan, Morgan Stanley and Jefferies are acting as joint book running managers for the offering.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on DNLI:
- Denali Therapeutics offers to sell $200M in common stock
- Denali Therapeutics price target raised to $29 from $26 at BofA
- Denali Therapeutics price target raised to $31 from $30 at Wedbush
- Denali Therapeutics: Promising Pipeline and Strategic Advancements Justify Buy Rating
- Denali Therapeutics: Promising Future with Strategic Agreements and Innovative Programs